Basic Information
MigVax was established by MIGAL as an SPV (Special Purpose Vehicle) and has been granted a global exclusive license by MIGAL to engage in the research, development, production, and commercialization of vaccines targeting human viruses, starting with COVID-19.
MigVax Ltd.
Israel
less than 15 people
January 01, 2020
migvax@migal.org.il
Enterprise Profile
Industrial Sector
Concept
Application Scenarios